secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-07-03T23:59:59+00:00
Accession:  0001641172-25-017653
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte closes $5.0M private placement of common stock, preferred and warrants
----------------------------------------------------------------------------

- Gross proceeds of $5.0M; $4.0M received at closing July 2, 2025; $1.0M due upon SEC registration effectiveness.
- Offering includes 2,382,084 common shares (or pre-funded warrants), 3,573,130 Series B convertible preferred shares, and 6,355,214 common warrants exercisable at $1.00/share.
- Series B preferred shares bear 8% cumulative non-compounding dividend, convertible 1:1, and grant holders two board seats.
- Net proceeds to be used for general corporate purposes and working capital; Spartan Capital served as placement agent.
- Post-offering, company believes stockholders' equity exceeds $2.5M and awaits Nasdaq compliance determination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225017653/0001641172-25-017653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225017653/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer